
Purpose To evaluate the feasibility, diagnostic yield, and safety of synchronous computed tomography (CT)–guided core needle biopsy and cryoablation for highly suspicious 1–2-cm pulmonary nodules. Materials and Methods This retrospective single-center study included 102 consecutive patients undergoing synchronous CT-guided core needle biopsy and cryoablation between August 2020 and October 2025. Treatment was undertaken on the basis of clinical and imaging suspicion before final histopathologic diagnosis. A cryoprobe was placed before biopsy to provide an intraprocedural landmark. Technical success, diagnostic yield, and adverse events were evaluated in all 102 patients; local tumor progression (LTP) and overall survival (OS) were evaluated separately in 81 patients with pathology-confirmed non–small cell lung cancer (NSCLC). Results Cryoablation technical success was 100% (102/102), and concurrent biopsy diagnostic yield was 87.3% (89/102). Biopsy identified 86 malignant diagnoses, including 81 NSCLCs. Mean nodule diameter was 1.52 cm (SD ± 0.30). Median follow-up in the NSCLC cohort was 34.5 months (interquartile range, 18.4–49.4 months). The cumulative incidence of recorded LTP was 8.8% at both 1 and 3 years, and OS rates were 100% and 90.8%, respectively. Pneumothorax requiring chest tube drainage occurred in 20.6% (21/102), and no procedure-related deaths were reported. Conclusions The synchronous biopsy and cryoablation approach was technically feasible and provided a specific histopathologic diagnosis in 87.3% of selected patients with highly suspicious 1.0–2.0-cm pulmonary nodules. Among patients with pathology-confirmed NSCLC, local control outcomes were within the range reported in similar cryoablation-only series.
Purpose To compare hemostatic effectiveness and subsequent pregnancy outcomes of gelatin sponge (GS) and n-butyl cyanoacrylate (nBCA) in emergency uterine artery embolization (UAE) for postpartum hemorrhage (PPH), with shock index (SI) as an indicator of bleeding severity. Materials and Methods The authors retrospectively reviewed 51 patients who underwent emergency UAE for uncontrolled PPH between January 2012 and December 2024. Hemostatic outcomes were evaluated in all patients. Forty-eight patients with SI data were stratified into 3 groups: SI < 1.0 (n = 19), 1.0 ≤ SI < 1.5 (n = 18), and SI ≥ 1.5 (n = 11). Pregnancy outcomes were assessed in 46 patients with uterine preservation and available SI data. Results Initial embolization used GS in 44 patients (86.3%) and nBCA in 7 patients (13.7%). The disseminated intravascular coagulation score was higher in the initial nBCA group than in the initial GS group (median, 9 vs 7; P =.017). Initial embolization succeeded in 41 patients (80.4%), including 34 (77.3%) of 44 with GS and 7 (100%) of 7 with nBCA (P =.320). Of 10 initial GS failures, 8 were converted to nBCA, and 2 underwent hysterectomy. Final hemostatic success was achieved in 49 patients (96.1%), including all 8 converted cases. Among 46 patients with uterine preservation and available SI data, 9 achieved pregnancy: 6 (19.4%) of 31 after GS alone and 3 (20.0%) of 15 after nBCA, including GS-to-nBCA conversion (P = 1.000). Conclusion nBCA was effective for hemostasis in emergency UAE for PPH, including after conversion from GS. Subsequent pregnancy rates were comparable between GS alone and nBCA through April 30, 2026.
Purpose To evaluate the effect of transarterial embolization (TAE) on tumor burden, renal function, and safety in renal angiomyolipoma (AML) and to identify drivers of between-study heterogeneity. Materials and Methods A systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and prospectively registered in PROSPERO. Major databases were searched through January 2024. Morphologic response was expressed as percentage reduction from baseline (random-effects ratio of means; medians converted by Wan method); proportions were pooled by arcsine transformation. Risk of bias was assessed with risk of bias in nonrandomized studies of interventions, risk of bias 2, and the Joanna Briggs Institute checklist. Results In total, 79 studies (1,798 patients) were included. TAE reduced tumor volume by 55.7% (95% confidence interval [CI], 49.3%–61.3%; I2 = 85.6%; k = 18) and diameter by 34.2% (95% CI, 29.1%–38.9%; I2 = 70.1%; k = 43). The interval to postprocedural imaging accounted for 50.7% of the between-study variance in volume reduction (P = .002); predicted reduction increased from 44% at 1 month to 63% at 36 months, a gradient 3 cohorts with serial imaging reproduced within study. Serum creatinine and estimated glomerular filtration rate showed no clinically meaningful change from baseline. Pooled technical and clinical success were 98% and 97%; adverse events other than postembolic syndrome occurred in 3% and postembolic syndrome in 46%. Conclusions TAE achieved substantial, strongly time-dependent tumor reduction with high procedural success and few adverse events. Renal function was stable relative to baseline, but no included study used a surveillance comparator. Standardized outcome definitions and prespecified imaging intervals are needed before pooled estimates can guide patient selection.